ANLN is associated with the progression of lung, pancreatic, and cervical cancers [18–20], whereas UBE2T is associated with proliferation in hepatocellular carcinoma, glioblastoma, gastric cancer, and renal cell carcinoma [21–25]. Here, ANLN is linked to hepatocellular carcinoma.